KR101678702B1 - 신장 세포 암종 치료용 3,3',4,4'-테트라하이드록시-2,2'-바이피리딘-ｎ,ｎ'-디옥시드 - Google Patents

신장 세포 암종 치료용 3,3',4,4'-테트라하이드록시-2,2'-바이피리딘-ｎ,ｎ'-디옥시드 Download PDF

Info

Publication number
KR101678702B1
KR101678702B1 KR1020117007204A KR20117007204A KR101678702B1 KR 101678702 B1 KR101678702 B1 KR 101678702B1 KR 1020117007204 A KR1020117007204 A KR 1020117007204A KR 20117007204 A KR20117007204 A KR 20117007204A KR 101678702 B1 KR101678702 B1 KR 101678702B1
Authority
KR
South Korea
Prior art keywords
compound
formula
pharmaceutical composition
administered
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117007204A
Other languages
English (en)
Korean (ko)
Other versions
KR20110073486A (ko
Inventor
제니 니스트롬
리사 부발
울프 닐슨
보르제 하랄드손
Original Assignee
제니 니스트롬
리사 부발
울프 닐슨
보르제 하랄드손
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제니 니스트롬, 리사 부발, 울프 닐슨, 보르제 하랄드손 filed Critical 제니 니스트롬
Publication of KR20110073486A publication Critical patent/KR20110073486A/ko
Application granted granted Critical
Publication of KR101678702B1 publication Critical patent/KR101678702B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020117007204A 2008-10-06 2009-10-06 신장 세포 암종 치료용 3,3',4,4'-테트라하이드록시-2,2'-바이피리딘-ｎ,ｎ'-디옥시드 Active KR101678702B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19531208P 2008-10-06 2008-10-06
US61/195,312 2008-10-06
US12/586,849 US8053430B2 (en) 2008-10-06 2009-09-29 Treatment of renal cell carcinoma
US12/586,849 2009-09-29
PCT/EP2009/062976 WO2010040750A1 (en) 2008-10-06 2009-10-06 3, 3', 4, 4' -tetrahydroxy-2, 2' -bipyridine-n, n' -dioxides for the treatment of renal cell carcinoma

Publications (2)

Publication Number Publication Date
KR20110073486A KR20110073486A (ko) 2011-06-29
KR101678702B1 true KR101678702B1 (ko) 2016-11-22

Family

ID=41395600

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117007204A Active KR101678702B1 (ko) 2008-10-06 2009-10-06 신장 세포 암종 치료용 3,3',4,4'-테트라하이드록시-2,2'-바이피리딘-ｎ,ｎ'-디옥시드

Country Status (11)

Country Link
US (2) US8053430B2 (cg-RX-API-DMAC10.html)
EP (1) EP2349268B1 (cg-RX-API-DMAC10.html)
JP (1) JP5340393B2 (cg-RX-API-DMAC10.html)
KR (1) KR101678702B1 (cg-RX-API-DMAC10.html)
CN (2) CN102170881B (cg-RX-API-DMAC10.html)
CA (1) CA2736322C (cg-RX-API-DMAC10.html)
DK (1) DK2349268T3 (cg-RX-API-DMAC10.html)
ES (1) ES2401671T3 (cg-RX-API-DMAC10.html)
PL (1) PL2349268T3 (cg-RX-API-DMAC10.html)
PT (1) PT2349268E (cg-RX-API-DMAC10.html)
WO (1) WO2010040750A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250083338A (ko) 2023-11-30 2025-06-10 가톨릭대학교 산학협력단 신장암 어셈블로이드 및 이의 제조 방법

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2552443B1 (en) * 2010-04-01 2021-07-14 Oncorena Ab Improved treatment of renal cell carcinoma
GB201103578D0 (en) * 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
CN105450495B (zh) * 2014-09-18 2018-09-21 中国电信股份有限公司 用于重新建立安全通信通道的方法、装置和系统
WO2024002909A1 (en) 2022-07-01 2024-01-04 Oncorena Ab Orellanine formulation
CN121335885A (zh) 2023-05-03 2026-01-13 奥科瑞纳股份公司 奥来毒素的合成

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713352A (en) 1981-08-31 1987-12-15 Sloan-Kettering Institute For Cancer Reseach Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
US6403373B1 (en) 1997-10-10 2002-06-11 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon, renal, and stomach cancer and methods of using these
US6440663B1 (en) 1998-10-05 2002-08-27 Ludwig Institute For Cancer Research Renal cancer associated antigens and uses therefor
AR029160A1 (es) 1999-04-08 2003-06-18 Schering Corp El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
CN1359941A (zh) 2000-12-20 2002-07-24 上海博德基因开发有限公司 一种新的多肽——人肾癌rage4抗原11.44和编码这种多肽的多核苷酸
RU2188026C1 (ru) 2001-01-12 2002-08-27 Ростовский научно-исследовательский онкологический институт Способ лечения рака почки
EP1712234B1 (en) 2001-09-12 2009-01-28 Novartis AG Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment
ATE537842T1 (de) 2002-07-01 2012-01-15 Wilex Ag Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms
DE10307928A1 (de) 2003-02-25 2004-09-16 Faustus Forschungs Cie. Translational Cancer Research Gmbh Verwendung von 1-(2-Chlorethyl)-1-nitroso-3-(2-hydroxyethyl)-urea zur Behandlung von Pankreaskarzinomen, Weichteilsarkomen, Hodentumoren, Lymphomen, Thymomen, Wilms Tumoren, Nierenkarzinomen, Melanomen, Lungentumoren, intracerebralen Metastasen, Tumoren im Kopf- und Halsbereich, und Mamma-Karzinomen
WO2006044779A1 (en) 2004-10-14 2006-04-27 Northwestern University Detection and treatment of renal cancer
CA2625741C (en) 2005-10-14 2013-08-06 Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Treating renal cancer using 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-methyl-benzaldehyde
EP1957115B8 (en) 2005-11-10 2014-03-05 Celldex Therapeutics, Inc. Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FREE RADICAL BIOLOGY AND MEDICINE, ELSEVIER SCIENCE, US, vol . 44, no. 8 , 31 January 2008

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250083338A (ko) 2023-11-30 2025-06-10 가톨릭대학교 산학협력단 신장암 어셈블로이드 및 이의 제조 방법

Also Published As

Publication number Publication date
US20100152243A1 (en) 2010-06-17
EP2349268A1 (en) 2011-08-03
CA2736322C (en) 2017-01-10
KR20110073486A (ko) 2011-06-29
PL2349268T3 (pl) 2013-06-28
CA2736322A1 (en) 2010-04-15
CN105147683A (zh) 2015-12-16
WO2010040750A1 (en) 2010-04-15
HK1218857A1 (zh) 2017-03-17
US20120077846A1 (en) 2012-03-29
ES2401671T3 (es) 2013-04-23
JP2012504584A (ja) 2012-02-23
DK2349268T3 (da) 2013-04-15
CN105147683B (zh) 2019-01-22
JP5340393B2 (ja) 2013-11-13
CN102170881A (zh) 2011-08-31
PT2349268E (pt) 2013-04-02
EP2349268B1 (en) 2013-01-16
US8349823B2 (en) 2013-01-08
CN102170881B (zh) 2015-07-22
HK1161116A1 (zh) 2012-08-24
US8053430B2 (en) 2011-11-08

Similar Documents

Publication Publication Date Title
JP2021175754A (ja) がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ
JP2002533404A (ja) 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法
JP2018515618A (ja) がん治療
CN112138024A (zh) 治疗严重形式的肺动脉高压的方法
EA029072B1 (ru) Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты
JP5340393B2 (ja) 腎細胞癌の治療のための３，３’，４，４’−テトラヒドロキシ−２，２’−ビピリジン−ｎ，ｎ’−ジオキシド
CN110290787B (zh) 用于抑制癌的转移及治疗癌的组合物
Ramezani et al. Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model
Gamucci et al. Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC—ECSG phase II clinical study
JP6197065B2 (ja) 腎細胞癌の改良された治療
KR102694803B1 (ko) A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용
US20210130782A1 (en) Engineered Exosomes to Detect and Deplete Pro-Tumorigenic Macrophages
RU2724341C1 (ru) Комбинированная композиция для предупреждения или лечения рака, содержащая производные бензофенонтиазола в качестве vda и ингибитор топоизомеразы
KR101824205B1 (ko) 암 예방 또는 치료용 약학적 조성물 및 이의 용도
KR20190094765A (ko) 암의 전이 억제 및 치료용 조성물
KR102558989B1 (ko) 항암 화학요법으로 인한 내성을 완화하고 항암 화학요법의 효과를 증진시키기 위한 약학적 조성물 및 그 용도
HK1161116B (en) 3, 3' 4, 4' -tetrahydroxy-2,2'-bipyridine-n, n'-dioxides for the treatment of renal cell carcinoma
EP3600261A1 (en) Encapsulated cells producing cytochrome p450 and methods of use thereof
US20210128683A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
HK1218857B (en) 3, 3', 4, 4' -tetrahydroxy-2, 2' -bipyridine-n, n'-dioxides for the treatment of renal cell carcinoma
HK40041555A (en) Method of treating severe forms of pulmonary hypertension
HK1138797A (zh) 肝癌治疗剂
HK1178458A (en) Therapeutic agent for liver cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190702

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10